BioVendor Group Demonstrates Unique IVD Platform and Immunoblot Test

BioVendor Group (Brno, Czech Republic) is demonstrating its IVD solutions in the form of a CLIA platform, a new generation of a unique immunoblot test for effective multiplex diagnostics, Microblot-Array, or its comprehensive sequencing solution using the NGS method at MEDICA 2023. MEDICA is the world's largest medical trade fair of all - with several thousand exhibitors from more than 60 nations in the exhibition halls. A wide range of innovative products and services from the fields of medical imaging, laboratory technology, diagnostics, health IT, mobile health as well as physiotherapy/orthopedic technology and medical consumables are being presented here.

At this year’s MEDICA, BioVendor is demonstrating the KleeYa fully automated analyzer which is versatile, fast, smooth, and intuitive, working like a perfectly coordinated orchestra. The operator is only required to set, run, and exit with KleeYa taking care of the rest and operating independently for a long time, thanks to the high-capacity consumable containers. With a graphical user interface, the operator can learn to control the fully automated system in minutes. Additionally, KleeYa software is designed to minimize the burden on laboratory staff. BioVendor is also highlighting Microblot–Array (MBA), a new generation of unique, immunoblot arrays in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing.

Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS. In addition, BioVendor is showcasing its new fastGEN technology for the examination of the mutation status of oncomarkers in samples. The technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with specially tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific, and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.

Related Links:
BioVendor Group